Pre-clinical data on HOOKIPA’s alternating 2-vector cancer therapeutics published in Cell Reports Medicine
March 04, 2021 07:00 ET
|
Hookipa Pharma Inc
Alternating, intravenous administration of two replicating arenaviral vectors induce tumor-specific responses exceeding 50% of the circulating CD8 T cells2-vector approach resulted in tumor cures and...
HOOKIPA Pharma to Participate in Upcoming H.C. Wainwright Global Life Sciences Conference
March 03, 2021 07:00 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, March 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Participate in Upcoming SVB Leerink Global Healthcare Conference
February 16, 2021 07:00 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, Feb. 16, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma Announces Closing of Public Offering of $80.9 Million of Common Stock and Preferred Stock, Including Full Exercise of Underwriters’ Option
December 11, 2020 16:20 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, Dec. 11, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Pharma Announces Pricing of Public Offering of Common Stock and Preferred Stock
December 08, 2020 22:00 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Preferred Stock
December 08, 2020 16:01 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of Advanced HPV16+ Cancers Shows Promising Anti-Tumor Activity and Favorable Tolerability
December 07, 2020 06:00 ET
|
Hookipa Pharma Inc
Results support first proof of concept for HOOKIPA’s replicating investigational single-vector immunotherapy in oncologyData demonstrate responses and stable disease in some head and neck cancer...
HOOKIPA Announces Positive Phase 2 Interim Safety, Immunogenicity, and Efficacy Data for its Cytomegalovirus Vaccine Candidate HB-101
November 30, 2020 06:00 ET
|
Hookipa Pharma Inc
Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV...
HOOKIPA Pharma Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
November 12, 2020 07:15 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, Nov. 12, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in November
November 11, 2020 07:00 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, Nov. 11, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...